Emergent BioSolutions | EBS - PE Price to Earnings


Emergent BioSolutions reported 14.4 in PE Price to Earnings for its fiscal quarter ending in September of 2022.





Pe Change Date
Acadia Pharmaceuticals 10.08 1.53 Mar/2026
Akebia Therapeutics 1.63K 1.6K Dec/2025
ALKERMES 39.33 19.8 Mar/2026
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Amarin 91.05 88.3 Jun/2023
ANI Pharmaceuticals 27.31 10.68 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Emergent BioSolutions 14.4 2.25 Sep/2022
Exelixis 13.91 588.4 Mar/2026
Glaxosmithkline 15.09 3.43 Mar/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Ironwood Pharmaceuticals 204.24 88.19 Dec/2024
Lexicon Pharmaceuticals 12.44 4.73 Jun/2021
Lonza 34.34 2.58 Dec/2025
Merck 16.52 2.6 Mar/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 28.09 807.38 Mar/2026
Pacira 38.58 14.1 Mar/2026
Pfizer 9.32 5.16 Mar/2026
PTC Therapeutics 9.98 3.25 Dec/2025
Sanofi 11.84 0.14 Mar/2026
Sarepta Therapeutics 27.27 0 Dec/2025
United Therapeutics 20.42 3.1 Mar/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023
Xoma 52.12 3.09 Sep/2022